02:32 , Mar 6, 2008 |  BC Extra  |  Financial News

TxCell raises EUR 10.5 million

TxCell (Sophia Antipolis, France) raised EUR 10.5 million ($15.9 million) in a series B round led by existing investor Auriga Partners. Other existing investors AXA Private Equity; Bioam Gestion; CDC Innovation; and Seventure also participated....
07:00 , Apr 2, 2007 |  BioCentury  |  Finance

Ebb & Flow

At the beginning of this year, SkyePharma (LSE:SKP; SKYE) laid out three goals it wanted to meet in 2007: complete a restructuring of its royalty financing with Paul Capital, divest its injectable business and complete...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Erytech Pharma S.A. board of directors update

Erytech Pharma S.A. , Lyon, France   Business: Drug delivery, Cancer   Appointed: Thierry Laugel, investment director at AGF Private Equity; Franck Lescure, partner at Auriga Partners; and Glenn Richard, investment manager at Axa Private...
08:00 , Oct 30, 2006 |  BioCentury  |  Finance

Ebb & Flow

One of the signs of a maturing sector is when the fortunes of one company don't cause either panic or euphoria in the rest of the group. Two examples in Europe last week - one...
02:09 , Oct 26, 2006 |  BC Extra  |  Financial News

Cytheris raises EUR 24.3 million

Cytheris (Paris, France) raised EUR 24.3 million ($30.7 million) in a series B round led by new investor CDC Enterprises Innovation. New investor ABN AMRO joined existing investors Axa Private Equity; BioAm; Credit Agricole; T2C2;...
07:00 , May 23, 2005 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe Company Name Country Raised Investors Arpida Switzerland $67.4 Swissfirst; Temasek Capital; Carnegie Asset Management; CDIB BioScience Ventures; CITA; MVI Medical Venture Investments; Schroder Ventures Life Sciences; Alta Berkeley Associates; Aventic; BioMedinvest;...
08:00 , Jan 24, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Mutabilis S.A. Paris, France Technology: Antivirulence for prevention of severe infection Disease focus: Infectious Clinical status: Research Founded: 2001 by Xavier Nassif University collaborators: University of Medicine Necker, Ecole Normale Superiore Corporate partners: 4SC AG...
08:00 , Jan 10, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
08:00 , Jan 3, 2005 |  BC Extra  |  Financial News

Neuro3d raises EUR 31.5 million

Neurology company Neuro3d (Mulhouse, France) raised EUR 31.5 million ($42.9 million) in a series C round co-led by Gilde Investment Management and AXA Private Equity. Other investors included Healthcare Private Equity (Scottish Widows Investment Partnership);...
07:00 , Oct 15, 2004 |  BC Extra  |  Financial News

TxCell raises EUR 10.5 million

Inflammation company TxCell (Nice, France) raised EUR 10.5 million ($13 million) in a series A round. Investors included Auriga Partners; AXA Private Equity; BioAm; CDC; and SPEF Venture; Inserm-Transfert; and company founders and management. TxCell...